Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 13.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 73,841 shares of the biotechnology company’s stock after purchasing an additional 8,645 shares during the period. Bank of New York Mellon Corp owned 0.35% of Enanta Pharmaceuticals worth $958,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. State Board of Administration of Florida Retirement System acquired a new position in Enanta Pharmaceuticals during the first quarter worth $118,000. Virtu Financial LLC purchased a new position in shares of Enanta Pharmaceuticals during the 1st quarter worth $191,000. Quest Partners LLC acquired a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at about $146,000. Pennant Investors LP purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at about $330,000. Finally, Acadian Asset Management LLC increased its position in Enanta Pharmaceuticals by 1.3% during the first quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock worth $14,906,000 after purchasing an additional 10,952 shares during the last quarter. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA stock opened at $11.28 on Friday. The firm has a market cap of $238.90 million, a P/E ratio of -1.81 and a beta of 0.59. The firm’s 50 day moving average price is $13.19 and its 200-day moving average price is $13.60. Enanta Pharmaceuticals, Inc. has a one year low of $8.08 and a one year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.07) EPS for the quarter, topping analysts’ consensus estimates of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The company had revenue of $17.97 million for the quarter, compared to analysts’ expectations of $17.44 million. During the same period in the prior year, the firm earned ($1.27) earnings per share. The firm’s revenue was down 4.9% compared to the same quarter last year. As a group, research analysts predict that Enanta Pharmaceuticals, Inc. will post -5.3 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on ENTA. JPMorgan Chase & Co. decreased their target price on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a report on Tuesday, August 6th. Evercore ISI upgraded Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $19.00.

Insider Buying and Selling

In other Enanta Pharmaceuticals news, insider Scott T. Rottinghaus sold 5,375 shares of Enanta Pharmaceuticals stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $17.08, for a total value of $91,805.00. Following the completion of the transaction, the insider now directly owns 21,717 shares of the company’s stock, valued at approximately $370,926.36. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, insider Scott T. Rottinghaus sold 4,299 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $15.07, for a total value of $64,785.93. Following the sale, the insider now directly owns 23,988 shares in the company, valued at $361,499.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Scott T. Rottinghaus sold 5,375 shares of Enanta Pharmaceuticals stock in a transaction on Monday, July 15th. The shares were sold at an average price of $17.08, for a total value of $91,805.00. Following the completion of the transaction, the insider now owns 21,717 shares of the company’s stock, valued at $370,926.36. The disclosure for this sale can be found here. 13.64% of the stock is owned by corporate insiders.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.